Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
CAMBRIDGE, Mass., Oct. 20, 2016 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2016 before the U.S. financial markets open on Wednesday, November 2, 2016.
Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 99282531. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
